This clinical trial is focused on studying Alzheimer’s Disease, a condition that affects memory and thinking skills. The trial will evaluate a treatment called AR1001, which is a film-coated tablet containing the active substance mirodenafil dihydrochloride. The study will compare the effects of AR1001 with a placebo tablet to understand its effectiveness and safety in people with early stages of Alzheimer’s Disease.
The purpose of the study is to assess how well AR1001 works over a period of 52 weeks. Participants will be randomly assigned to receive either the AR1001 tablet or a placebo tablet. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations about the treatment.
Throughout the study, participants will take the tablets orally and will be monitored regularly to track changes in their condition. The main focus will be on changes in their cognitive abilities, daily living activities, and mood over the course of the year. The study aims to provide valuable information about the potential benefits of AR1001 for individuals with early Alzheimer’s Disease.
Czechia 
Denmark 
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands 
